Reviewing Case Reports and the Droperidol Warning: FDA Response [1]

Anesthesia and Analgesia

Volumn 97, Issue 5, 2003, Pages 1542-

  Chang, Nancy ^a   Simone, Arthur ^a   Schultheis, Lester ^a   Rappaport, Bob ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROPERIDOL;

ANESTHESIST; CASE REPORT; DATA BASE; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LONG QT SYNDROME; MEDICAL DECISION MAKING; MEDICAL INFORMATICS; PRIORITY JOURNAL; TORSADE DES POINTES;

EID: 0142150206     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000077671.77618.f9     Document Type: Letter

References (7)

1. Ashraf SH, Tong JG. Food and Drug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003;96:1377-9.
2. Drolet B, Zhang S, Deschenes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999;10:1597-604.
3. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994;79:983-6.
4. Guy JM, Andre-Fouet X, Porte J, et al. Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol [in French]. Ann Cardiol Angeiol (Paris) 1991;40:541-5.
5. Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-52.
6. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997;17:531-7.
7. Desai M, Pinto M, Adigun A, et al. Pharmacokinetics and QT interval pharmacodynamics of single intravenous doses of droperidol. 2003 FDA Science Forum.